Efficacy and safety of Nrf2 activators for schizophrenia: a systematic review and meta-analysis.

Eur Arch Psychiatry Clin NeurosciMay 19, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Masakazu Okazaki, Kenji Sakuma, Hikaru Jo et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of Nrf2 activators in conjunction with antipsychotic treatments for schizophrenia, involving 16 randomized-controlled trials with 953 participants. Curcumin demonstrated marginal superiority over placebo for overall symptom improvement (standardized mean difference = -0.53), while sulforaphane was associated with a lower all-cause discontinuation rate compared to placebo.

Key findings

  • Curcumin showed a standardized mean difference of -0.53 for overall symptom improvement compared to placebo.
  • Sulforaphane resulted in a lower all-cause discontinuation rate than placebo.
  • Curcumin significantly reduced positive and negative symptoms and PANSS-G scores compared to placebo.
  • Sulforaphane decreased total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels.

Why it matters

Understanding the efficacy and safety of adjunctive Nrf2 activators can inform treatment strategies for schizophrenia, particularly in enhancing symptom management and improving patient adherence to therapy.

Source

PubMed · PMID 42154264Free full text on PubMed Central

Published in Eur Arch Psychiatry Clin Neurosci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.